Literature DB >> 267431

Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage.

P J Fialkow, R J Jacobson, T Papayannopoulou.   

Abstract

Glucose-6-phosphate dehydrogenase (G-6-PD) isoenzymes types of granulocytes were determined in eight women with chronic myelocytic leukemia (CML). The patients were heterozygous at the X-linked G-6-PD locus for the common gene, GdB, and a variant, such as GdA, so that both B and A enzyme types were found in skin cells. In contrast to these normal cells, only one G-6-PD type was found in CML granulocytes. The fact that such single-enzyme phenotypes are found in CML granulocytes, but not in nonleukemic granulocytes, provides strong evidence that the disease has a clonal origin. Single-enzyme phenotypes were also found in erythrocytes, platelets and cultured blood macrophages indicating that these cells have a common stem cell which is the site of the abnormality in CML. In the one studied patient, no evidence was found for involvement of cultured marrow fibroblasts. Clonal origin of CML virtually excludes cell recruitment as a sole pathogenetic mechanism. Either the leukemia arises as a consequence of a rare initial event in a single cell, or a series of events occurs in a clone such that it evolves into CML, or both.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 267431     DOI: 10.1016/0002-9343(77)90124-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  119 in total

1.  Hematologic disease induced in BALB/c mice by a bcr-abl retrovirus is influenced by the infection conditions.

Authors:  A G Elefanty; S Cory
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

2.  Extinction models for cancer stem cell therapy.

Authors:  Mary Sehl; Hua Zhou; Janet S Sinsheimer; Kenneth L Lange
Journal:  Math Biosci       Date:  2011-10-06       Impact factor: 2.144

Review 3.  Stem cells in prostate cancer initiation and progression.

Authors:  Devon A Lawson; Owen N Witte
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

Review 4.  Aging, B lymphopoiesis, and patterns of leukemogenesis.

Authors:  Robert A J Signer; Encarnacion Montecino-Rodriguez; Kenneth Dorshkind
Journal:  Exp Gerontol       Date:  2006-12-20       Impact factor: 4.032

5.  Age-related defects in B lymphopoiesis underlie the myeloid dominance of adult leukemia.

Authors:  Robert A J Signer; Encarnacion Montecino-Rodriguez; Owen N Witte; Jami McLaughlin; Kenneth Dorshkind
Journal:  Blood       Date:  2007-06-06       Impact factor: 22.113

6.  Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation.

Authors:  Annelie E Abrahamsson; Ifat Geron; Jason Gotlib; Kim-Hien T Dao; Charlene F Barroga; Isabel G Newton; Francis J Giles; Jeffrey Durocher; Remi S Creusot; Mobin Karimi; Carol Jones; James L Zehnder; Armand Keating; Robert S Negrin; Irving L Weissman; Catriona H M Jamieson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

7.  Establishment of the DU.528 human lymphohemopoietic stem cell line.

Authors:  J Kurtzberg; S H Bigner; M S Hershfield
Journal:  J Exp Med       Date:  1985-11-01       Impact factor: 14.307

8.  An in vitro model for cytogenetic conversion in CML. Interferon-alpha preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture.

Authors:  J J Cornelissen; R E Ploemacher; B W Wognum; A Borsboom; H C Kluin-Nelemans; A Hagemeijer; B Löwenberg
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

Review 9.  Right on target: eradicating leukemic stem cells.

Authors:  Daniela S Krause; Richard A Van Etten
Journal:  Trends Mol Med       Date:  2007-11-05       Impact factor: 11.951

10.  A 41-kilodalton protein is a potential substrate for the p210bcr-abl protein-tyrosine kinase in chronic myelogenous leukemia cells.

Authors:  E Freed; T Hunter
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.